Cargando…
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
AIM: SARS-CoV-2 infection has been divided by scientific opinion into three phases: the first as asymptomatic or slightly symptomatic and the second and the third with greater severity, characterized by a hyperinflammatory and fibrotic state, responsible for lung lesions, in some cases fatal. The de...
Autores principales: | Ferrara, Francesco, Granata, Giovanni, Pelliccia, Chiara, La Porta, Raffaele, Vitiello, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320911/ https://www.ncbi.nlm.nih.gov/pubmed/32594204 http://dx.doi.org/10.1007/s00228-020-02947-4 |
Ejemplares similares
-
Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016) -
The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020) -
Online tree expansion could help solve the problem of scalability in Bayesian phylogenetics
por: Truszkowski, Jakub, et al.
Publicado: (2023) -
COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy
por: Vitiello, Antonio, et al.
Publicado: (2020) -
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)